Article Text

PDF
Extended report
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
  1. Henrik Christian Leffers1,2,
  2. Mikkel Østergaard1,2,
  3. Bente Glintborg3,
  4. Niels Steen Krogh4,
  5. Heidi Foged5,
  6. Ulrik Tarp6,
  7. Tove Lorenzen7,
  8. Annette Hansen2,8,
  9. Michael Sejer Hansen8,
  10. Martin Skov Jacobsen9,
  11. Lene Dreyer10,
  12. Merete Lund Hetland1,2 on behalf of all departments of rheumatology in Denmark
  1. 1Department of Rheumatology, Copenhagen University Hospital Glostrup, Glostrup, Denmark
  2. 2The Danish Rheumatologic Database (DANBIO), Glostrup, Denmark
  3. 3Department of Rheumatology, Holbæk Hospital, Hellerup, Denmark
  4. 4Zitelab Aps, Copenhagen, Denmark
  5. 5Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark
  6. 6Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
  7. 7Department of Rheumatology, Vejle Hospital, Vejle, Denmark
  8. 8Department of Rheumatology, Copenhagen University Hospital Gentofte, Gentofte, Denmark
  9. 9Department of Rheumatology, Randers Hospital, Randers, Denmark
  10. 10Department of Rheumatology, Rigshospitalet, Copenhagen, Denmark
  1. Correspondence to Henrik Christian Leffers, Department of Rheumatology, Copenhagen University Hospital Glostrup, Nordre Ringvej 57, 2600 Glostrup, Denmark; hsk967{at}alumni.ku.dk

Abstract

Objectives To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry.

Methods 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made.

Results Median (IQR) disease duration was 8.5 (3–14)/9 (3–12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7–6.1), 3.4 (2.7–4.9) and 3.3 (2.5–4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7–6.2), 2.9 (2.3–4.0) and 2.5 (1.9–4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumab-treated patients.

Conclusions In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.

Statistics from Altmetric.com

Footnotes

  • Funding HCL received a study grant from the Danish Agency for Science, Technology and innovation, Ministry of Science, Technology and innovation, Denmark (non-commercial).

  • Competing interests MLH received consulting fees, speaking fees and/or research grants from Abbott, Centocor, Roche, Schering-Plough, UCB-Nordic and Wyeth (less than US$10 000 each), and on behalf of DANBIO, she has received grants from Abbott, Bristol-Myers Squibb, Roche, Schering-Plough, UCB-Nordic and Wyeth (more than US$10 000 each). MØ received consulting fees, speaking fees and/or research grants from Abbott, Amgen, Bristol-Meyers Squibb, Centocor, Genmab, GlaxoSmithKline, Novo Nordisk, Pfizer, Roche, Schering-Plough, UCB-Nordic and Wyeth (less than US$10 000 each).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.